An interventional study of Blood Flow Restriction Aerobic Exercise Training and Conventional Aerobic Exercise Training in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Istinye University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Istinye University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.
Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 160th largest by planned enrollment of the 188 interventional ones that give a count, is one of 27 that started in 2025, is one of 122 with no phase, reaches primary completion later than 40 of the 67 other live ones, and was the 220th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–75
University of Yalova · Sites in Turkey
Ages 18+
Çanakkale Onsekiz Mart University · Sites in Turkey
Ages 40+
Inonu University · Sites in Turkey
Ages 40–80
AstraZeneca · Sites in Turkey
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 45 · Phase 4 12
First in 2002; this study’s year is marked. 27 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 72 across the 188 interventional studies, 77 across the 60 observational. Of the 164 that completed or were terminated, 39 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 248 have an industry lead sponsor. The 10 most frequent:
Istinye University is the lead sponsor of 224 studies on the registry; 96 are open to participants now.
Istinye University has 3 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07581132Akdeniz UniversityInvestigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients | 2026-12-10 |
| NCT05738720Saglik Bilimleri UniversitesiEffect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD | 2026-12-20 |
| NCT07469111Inonu UniversityEffects Of Low-Load Blood Flow Restriction Training Of The Upper Extremity In Patients With Chronic Obstructive Pulmonary Disease | 2026-12-25 |
| NCT07087626Erzurum City HospitalCOPD Assessment Test Score and Perioperative Risk in COPD | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose:
This study aims to compare the effects of the classical pulmonary rehabilitation (PR) program and blood flow restriction (BFR) applied during low-intensity aerobic exercise within PR on systemic inflammation, hypoxemia, exercise capacity, pulmonary function, respiratory muscle strength, and quality-of-life parameters in individuals with COPD.
Methods:
This randomized controlled study will include 34 individuals with COPD, allocated into a BFR aerobic group and a control group. Both groups will receive core PR components, including diaphragmatic breathing, pursed-lip breathing, respiratory muscle training, and peripheral muscle strengthening. The BFR group will perform low-intensity aerobic exercise with blood flow restriction, while the control group will perform moderate-intensity aerobic exercise without BFR in accordance with standard PR protocols. All sessions will be supervised by a physiotherapist, twice per week, for eight weeks. Systemic inflammation markers, arterial blood gases, pulmonary function, exercise capacity, quality of life, and symptom scores will be assessed before PR, after the 8th session, and at the end of the program. Data will be analyzed using SPSS 26.0.
Expected Contribution:
This study aims to provide evidence-based insights into the physiological and clinical effects of low-intensity BFR aerobic exercise within PR and to determine its potential advantages compared with classical PR. Additionally, it seeks to clarify whether low-intensity BFR aerobic exercise may serve as a better-tolerated alternative for COPD patients who experience exercise intolerance during moderate-intensity aerobic training.
RATIONALE AND AIM OF THE STUDY
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by airflow limitation, systemic inflammation, impaired gas exchange, and significant skeletal muscle dysfunction. Individuals with COPD frequently experience reduced exercise capacity, peripheral muscle weakness, chronic hypoxemia, fatigue, sleep disturbances, and decreased quality of life. These systemic features contribute to increased symptom burden and diminished functional independence.
Pulmonary rehabilitation (PR) is an established intervention that improves exercise tolerance, reduces dyspnea, and enhances quality of life. However, many patients are unable to sustain high-intensity exercise because of ventilatory limitations, early muscle fatigue, or oxygen desaturation. This creates a need for alternative exercise strategies that provide an adequate physiological stimulus while remaining tolerable for individuals with limited exercise reserve.
Blood Flow Restriction (BFR) exercise is a low-intensity training method that induces localized hypoxic and metabolic stress, promoting physiological adaptations such as increased muscle activation and improved functional performance. Although early findings suggest potential benefits of BFR, its effects when integrated into a PR program-particularly on systemic inflammation, oxygenation, respiratory muscle function, and exercise capacity-have not been comprehensively investigated.
This study aims to compare conventional PR with PR combined with low-intensity aerobic exercise performed under BFR in individuals with stable COPD. The study will evaluate systemic inflammatory markers, oxygenation and hypoxemia responses, exercise capacity, spirometric measurements, respiratory muscle strength, arterial blood gases, and patient-reported symptoms. By assessing physiological, functional, and subjective outcomes together, the study seeks to determine the potential added value of BFR-assisted aerobic training within pulmonary rehabilitation.
The findings are expected to clarify whether BFR can enhance the effectiveness of PR, provide a more tolerable training option for individuals with limited exercise capacity, and support the development of individualized rehabilitation strategies for people with COPD.
DESIGN For this study, the sample will consist of patients aged 40-80 years with a diagnosis of COPD who are referred to the Pulmonary Rehabilitation Unit of the Department of Pulmonology at Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences, by a pulmonology specialist. Participants will be randomly assigned into two groups using a computerized randomization method: a routine pulmonary rehabilitation group (control group) and a group receiving blood flow restriction (BFR) during aerobic exercise, which is one of the parameters of pulmonary rehabilitation (intervention group). Pulmonary rehabilitation programs for both groups will be administered by an experienced physiotherapist under the supervision of a pulmonology specialist. Before initiating the rehabilitation program, the cardiovascular suitability of the patients for pulmonary rehabilitation will be determined by a cardiologist. The program will begin once medical approval indicating "suitable for pulmonary rehabilitation" has been obtained. The study has a multidisciplinary and multidimensional structure.
Both groups will participate in a total of 16 pulmonary rehabilitation sessions conducted twice weekly for 8 weeks within the hospital. Each session will last 60 minutes.
2.1. Intervention Group In the intervention group, the pulmonary rehabilitation program will include the active cycle of breathing techniques, diaphragmatic breathing, pursed-lip breathing, and respiratory muscle training. In addition, a bilateral resistance exercise program will be given to target the shoulder flexors, elbow flexors, and quadriceps muscle groups. Furthermore, aerobic exercise with blood flow restriction (BFR) will be performed on a cycle ergometer.
Active Cycle of Breathing Techniques (ACBT) ACBT consists of a series of techniques applied to improve ventilation efficiency. These techniques strengthen respiratory muscles and enhance respiratory function. In this cycle, various breathing strategies are applied consecutively to increase ventilatory capacity. In COPD patients, these techniques help open the airways and optimize ventilation. Techniques include deep breathing, breath-holding, and controlled exhalation strategies.
Diaphragmatic Breathing Diaphragmatic breathing is a method of inhalation performed using the diaphragm instead of the accessory muscles. This technique increases ventilation of the lower lungs, enhances oxygen uptake, and reduces respiratory muscle fatigue. In COPD patients, diaphragmatic breathing reduces the work of breathing and allows patients to breathe more efficiently.
Pursed-Lip Breathing Pursed-lip breathing is a technique that helps keep the airways open during exhalation. The patient exhales slowly through lightly pursed lips during breathing. This technique facilitates overcoming airway resistance, regulates airflow in COPD patients, and enables more effective breathing. It also helps correct ventilation-perfusion imbalances and reduces dyspnea.
Respiratory Muscle Training In this study, inspiratory muscle training will be performed using the Powerbreathe Medic Plus (gray) device twice a week for 8 weeks. The initial load will be set at 30% of the patient's measured maximal inspiratory pressure (MIP). Progression will be made according to the perceived difficulty level reported during exercise based on the Modified Borg Scale (0-10), keeping the perceived exertion (RPE) between 3-4 and increasing the load by 5-10% each week. The goal will be to reach 60% of the MIP. The training will follow a protocol of 5 breaths × 6 sets, with rest intervals adjusted based on patient tolerance.
Peripheral Muscle Training Resistance training will be applied as 2 sets × 8 repetitions at an RPE of 3-4 on the Modified Borg Scale. Targeted muscle groups will include the quadriceps femoris, shoulder flexors, and elbow flexors.
BFR + Aerobic Exercise Program BFR will be applied using a wireless AirBands cuff placed proximally on the thigh at the level of the femoral artery at 45% of the individual limb occlusion pressure (LOP). Aerobic exercise will be performed on a cycle ergometer at 40-60% of the target heart rate (low-moderate intensity). The target heart rate will be determined using the Karvonen formula [THR=HRmax-HRrest)×%intensite]+HRrest]. Each session will consist of 3 minutes of warm-up, 15 minutes of exercise, and 3 minutes of cool-down (21 minutes total). BFR will begin after warm-up and remain inflated throughout the exercise. At the end of the session, the cuff will be released, followed by a 5-minute reactive hyperemia period. Exercise progression will be individualized according to the MBS RPE scores recorded during each session; the target perceived effort will be kept between 2-3 (light-moderate), and workload (watts) will be increased by 5-10% weekly as tolerated.
2.2. Control Group In the control group, the pulmonary rehabilitation program will include the active cycle of breathing techniques, diaphragmatic breathing, pursed-lip breathing, and respiratory muscle training. In addition, a bilateral resistance training program targeting the shoulder flexors, elbow flexors, and quadriceps muscle groups will be implemented. Aerobic exercise training will be performed on a cycle ergometer without the use of BFR.
Active Cycle of Breathing Techniques (ACBT) ACBT consists of techniques applied to improve the efficiency of breathing. These techniques strengthen the respiratory muscles and enhance respiratory function. Various breathing strategies are applied consecutively to increase ventilatory capacity. In COPD patients, these strategies open the airways, optimize ventilation, and improve airflow. The cycle includes techniques such as deep breathing, breath-holding, and controlled exhalation.
Diaphragmatic Breathing Diaphragmatic breathing is a method of breathing performed by effectively using the diaphragm rather than the abdominal or accessory muscles. This technique improves ventilation of the lower lungs, increases oxygen intake, and reduces respiratory muscle fatigue. In COPD patients, diaphragmatic breathing decreases the work of breathing and helps patients breathe more efficiently.
Pursed-Lip Breathing Pursed-lip breathing is a technique that helps maintain airway patency during exhalation. The patient exhales slowly through lightly pursed lips. This technique facilitates overcoming airway resistance, regulates airflow in COPD patients, and makes breathing more efficient. It also corrects ventilation imbalances and reduces dyspnea.
Respiratory Muscle Training Inspiratory muscle training will be performed using the Powerbreathe Medic Plus (gray) device, twice a week for 8 weeks. The initial training load will be set at 30% of the patient's measured maximal inspiratory pressure (MIP). Progression will be based on perceived exertion reported during exercise according to the Modified Borg Scale (0-10), maintaining an RPE of 3-4, with weekly increases of 5-10% in resistance. The goal is to reach 60% of the MIP. Training will follow the "5 breaths × 6 sets" format with individualized rest intervals according to patient tolerance.
Peripheral Muscle Training Resistance training will be applied as 2 sets of 8 repetitions at an RPE of 3-4. Targeted muscle groups will include the quadriceps femoris, shoulder flexors, and elbow flexors.
Aerobic Exercise Program The aerobic exercise protocol on the cycle ergometer will be performed at 60-80% of the target heart rate. The target heart rate will be calculated using the Karvonen formula, which incorporates the heart rate reserve (HRR):[THR=(HRmax-HRrest)×%intensite]+HRrest] This formula provides a more accurate estimation of the training heart rate, especially in clinical populations. Aerobic training will be performed twice weekly for 8 weeks, with each session consisting of 3 minutes of warm-up, 15 minutes of target aerobic exercise, and 3 minutes of cool-down (21 minutes total). Pedal resistance and pedaling speed will be adjusted according to the Borg RPE scores reported during the session. The target RPE during exercise will be kept at 3-4, with weekly increases of 5-10% in workload.
Sample Size Calculation
The primary outcome of the study is the change in 6MWT distance. Based on previously reported clinically meaningful differences in 6MWT distance in individuals with COPD and assuming a medium effect size, a power analysis was performed using a significance level of 0.05 and a power of 80%. The calculation indicated that 17 participants per group (34 in total) would be sufficient to detect clinically relevant between-group differences in 6MWT distance.
All data will be analyzed using a statistical software package. The normality of distribution for continuous variables will be assessed using appropriate tests. Parametric variables will be presented as mean ± standard deviation, and non-parametric variables as median with interquartile range.
Baseline differences between groups will be analyzed using independent samples t-tests or Mann-Whitney U tests, as appropriate. Categorical variables will be compared using the chi-square test.
Within-group changes from pre- to post-intervention will be evaluated using paired samples t-tests or Wilcoxon signed-rank tests, depending on data distribution. Group × time interactions will be examined using two-way repeated measures ANOVA or linear mixed models.
Correlations between changes in inflammatory markers and changes in 6MWT distance will be analyzed using appropriate correlation coefficients. A p-value of \<0.05 will be considered statistically significant for all analyses, and effect sizes will be reported to aid interpretation of clinical relevance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will perform low-intensity aerobic exercise on a cycle ergometer under blood flow restriction (BFR) as part of pulmonary rehabilitation. BFR pressure will be applied bilaterally to the proximal thighs using pneumatic cuffs at 40-50% of each participant's limb occlusion pressure. Sessions will include warm-up, 15 minutes of aerobic exercise, and cool-down, supervised by a physiotherapist. No aerobic exercise without BFR will be performed in this arm.
Behavioral: Blood Flow Restriction Aerobic Exercise Training
Participants in this arm will perform standard aerobic exercise on a cycle ergometer as part of conventional pulmonary rehabilitation without blood flow restriction. Exercise intensity will be prescribed at 60-80% of the target heart rate calculated using the Karvonen formula. Each session will include a 3-minute warm-up, 15 minutes of continuous aerobic exercise, and a 3-minute cool-down. Exercise intensity, frequency, and duration will be matched to the BFR aerobic exercise group. All sessions will be supervised by an experienced physiotherapist. No blood flow restriction will be applied in this arm.
Behavioral: Conventional Aerobic Exercise Training
Blood Flow Restriction Aerobic Exercise Training Participants will undergo aerobic exercise performed with blood flow restriction (BFR) applied to both thighs using pneumatic cuffs positioned at the proximal portion of the lower limbs. Cuff pressure will be individualized for each participant based on limb occlusion pressure (LOP), determined by Doppler assessment. During training, cuffs will be inflated to 40-50% of the participant's LOP and will remain inflated throughout the aerobic exercise phase. Sessions will include warm-up, continuous low-intensity cycling, and cool-down, supervised by a physiotherapist. The purpose of this intervention is to induce physiological adaptations associated with BFR, such as increased metabolic stress and muscular activation, while using low mechanical load.
Participants in this group will perform aerobic exercise on a cycle ergometer without blood flow restriction (BFR) as part of standard pulmonary rehabilitation. The aerobic exercise protocol will be performed at 60-80% of the participant's target heart rate (THR), calculated using the Karvonen formula: THR = \[(HRmax - HRrest) × % intensity\] + HRrest. Training will be performed twice per week for a total of 8 weeks and will include 3 minutes of warm-up, 15 minutes of target-intensity aerobic cycling, and 3 minutes of cool-down (total duration: 21 minutes). Pedal resistance and cadence will be adjusted according to the Borg Rating of Perceived Exertion (RPE), with the target RPE maintained between 3 and 4. Exercise intensity (watt level) will be progressed weekly by approximately 5-10%, aligned with tolerance and RPE scores (Patterson et al., 2019). No BFR will be applied at any stage of the intervention.
Change in Exercise Capacity
Exercise capacity will be evaluated using the 6-Minute Walk Test (6MWT), conducted according to ATS guidelines in a 30-meter corridor. The total distance walked in 6 minutes (6MWD) will be recorded as the primary indicator of functional exercise capacity. The outcome measure will assess the change in 6MWT distance from baseline to 8 weeks following the intervention in COPD patients undergoing pulmonary rehabilitation with or without blood flow restriction (BFR). An increase in 6MWD reflects improvement in exercise capacity.
Time frame: Baseline and 8 weeks after intervention
Change in Systemic Inflammation (CRP Levels)
Systemic inflammation will be assessed using serum C-reactive protein (CRP) levels. Blood samples will be collected at baseline and after the 8-week intervention. CRP concentration will be analyzed using standard laboratory biochemical methods. Changes in CRP levels will be used to evaluate the effect of the intervention on systemic inflammatory status.
Time frame: Baseline and 8 weeks after intervention
Change in Systemic Inflammation (RDW Levels)
Red cell distribution width (RDW), an inflammatory and hypoxia-related hematologic marker, will be measured using complete blood count analysis. RDW values obtained at baseline and after the 8-week intervention will be compared to evaluate changes in systemic inflammation.
Time frame: Baseline and 8 weeks after intervention
Change in Arterial Oxygen Partial Pressure (PaO₂)
Arterial oxygen partial pressure (PaO₂) will be measured using arterial blood gas analysis (ABG). Blood samples will be collected at baseline and after the 8-week intervention. PaO₂ values will be used to assess changes in arterial oxygenation and respiratory gas exchange following the intervention.
Time frame: Baseline and 8 weeks after intervention
Change in Respiratory Function (FEV₁)
Respiratory function will be assessed using forced expiratory volume in 1 second (FEV₁), measured via standardized spirometry following ATS/ERS guidelines. FEV₁ values will be recorded in liters and as a percentage of the predicted value. Measurements obtained at baseline and after the 8-week intervention will be compared to evaluate changes in pulmonary function.
Time frame: Baseline and 8 weeks after intervention
Change in Respiratory Muscle Strength (MIP)
Respiratory muscle strength will be assessed using maximal inspiratory pressure (MIP), measured with an electronic pressure manometer following ATS/ERS standards. MIP represents the maximum negative pressure generated during a forceful inspiratory effort against an occluded airway. Measurements obtained at baseline and after the 8-week intervention will be compared to evaluate changes in inspiratory muscle strength.
Time frame: Baseline and 8 weeks after intervention
Change in Peripheral Muscle Strength (Quadriceps Strength)
Peripheral muscle strength will be assessed by measuring isometric quadriceps muscle force using a handheld digital dynamometer (Lafayette Manual Muscle Tester). Participants will perform maximal voluntary isometric contraction for 3-5 seconds in a standardized seated position. Three trials will be recorded with 30 seconds of rest between attempts, and the highest value (in Newtons) will be used for analysis. Measurements obtained at baseline and after the 8-week intervention will be compared to evaluate changes in quadriceps strength.
Time frame: Baseline and 8 weeks after intervention
Change in Dyspnea (mMRC Score)
Dyspnea severity will be assessed using the Modified Medical Research Council (mMRC) Dyspnea Scale, which rates perceived breathlessness from 0 (no dyspnea) to 4 (severe dyspnea during minimal activity). mMRC scores obtained at baseline and after the 8-week intervention will be compared to evaluate changes in dyspnea levels.
Time frame: Baseline and 8 weeks after intervention
Plan to share: No
Ran from Dec 2025 to primary completion in Jun 2026, 6 months.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →